BioSpace News Archive

Albireo Pharma, Inc. announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022.

Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, announced the issuance of U.S. Patent No. 11,446,344.

Autonomous Medical Devices Incorporated (AMDI) announced today that it will be presenting data on its Q-NAb™ Test at the 28th AACC International CPOCT Symposium: Meeting Evolving Patient Needs Using Point-of-Care Testing in Montreal September 21-23, 2022.

Verismo Therapeutics, a clinical-stage biotechnology company and a Penn-spinout behind the novel KIR-CAR platform technology, today announced that is has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110.

Cellistic and Celyad Oncology announced a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel.

XVIVO Perfusion AB XVIVO has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration for their Liver Assist device, indicated for ex-vivo oxygenated machine perfusion for preservation of donor livers prior to transplantation.

Photocure ASA, The Bladder Cancer Company, announces the publication of first results from the Laser III clinical study in the medical journal, European Urology.

Bavarian Nordic A/S announced a revised contract with the Public Health Agency of Canada to supply doses of IMVAMUNE® smallpox vaccine at a value of approximately USD 234 million in addition to USD 180 million in contract options.

The two biotech leaders have embarked on a research project to streamline manufacturing of non-viral CRISPR gene editing components; the goal is to improve the editing efficiency and cell viability of non-viral based cell therapies

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced the appointment of Glenn E. Pauly as Head of Commercial.